Presentation is loading. Please wait.

Presentation is loading. Please wait.

Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1,

Published byPedro Henrique Cerveira Modified over 5 years ago

Similar presentations

Presentation on theme: "Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1,"— Presentation transcript:

1 Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1, UNCOVER-2, and UNCOVER-3  Alexander Egeberg, MD, PhD, Jashin J. Wu, MD, Neil Korman, MD, PhD, James A. Solomon, MD, PhD, Orin Goldblum, MD, Fangyi Zhao, PhD, Lotus Mallbris, MD, PhD  Journal of the American Academy of Dermatology  Volume 79, Issue 1, Pages e8 (July 2018) DOI: /j.jaad Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

2 Fig 1 Low-density lipoprotein (LDL)-to–high-density lipoprotein (HDL) ratio in the induction period (UNCOVER-1, UNCOVER-2, and UNCOVER-3; weeks 0-12) and maintenance period (UNCOVER-1 and UNCOVER-2; weeks 12-60; only placebo [PBO] and ixekizumab every 4 weeks [IXEQ4W]) when patients were treated with PBO, IXEQ4W, or ixekizumab every 2 weeks (IXEQ2W). Induction period results derived from the primary psoriasis placebo-controlled integrated analysis set, and maintenance period results derived from the psoriasis maintenance integrated analysis set. Journal of the American Academy of Dermatology  , e8DOI: ( /j.jaad ) Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

3 Supplemental Fig 1 Results from UNCOVER-1, UNCOVER-2, and UNCOVER-3 were integrated into the primary psoriasis placebo-controlled integrated analysis set (weeks 0-12; UNCOVER-1, UNCOVER-2, and UNCOVER-3) (A), the primary psoriasis placebo- and active-controlled integrated analysis set (weeks 0-12; UNCOVER-2 and UNCOVER-3) (B), and the psoriasis maintenance integrated analysis set (weeks 12-60; UNCOVER-1 and UNCOVER-2) (C). ETN, Etanercept; IXEQ2W, ixekizumab every 2 weeks; IXEQ4W, ixekizumab every 4 weeks; PBO, placebo. Journal of the American Academy of Dermatology  , e8DOI: ( /j.jaad ) Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

4 Supplemental Fig 2 Low-density lipoprotein (LDL)-to–high-density lipoprotein (HDL) ratio in the ixekizumab integrated induction period for UNCOVER-2 and UNCOVER-3 (psoriasis placebo- and active-controlled integrated analysis set) when patients were treated with placebo (PBO), ixekizumab every 4 weeks (IXEQ4W), ixekizumab every 2 weeks (IXEQ2W), or etanercept (ETN) biweekly. Journal of the American Academy of Dermatology  , e8DOI: ( /j.jaad ) Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

Download ppt "Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1,"

Similar presentations

Use of the diagonal mattress suture to prevent dog-ear formation

Use of the diagonal mattress suture to prevent dog-ear formation
Yin-Shuo Chang, MD, Yu-Chen Huang, MD 

Yin-Shuo Chang, MD, Yu-Chen Huang, MD 
Clavi syphilitici–an unusual presentation of syphilis

Clavi syphilitici–an unusual presentation of syphilis
Optimal time to provide skin cancer and photoprotection education to pediatric solid organ transplant recipients  Lily Chen, BA, Feng Gao, MD, PhD, MPH,

Optimal time to provide skin cancer and photoprotection education to pediatric solid organ transplant recipients  Lily Chen, BA, Feng Gao, MD, PhD, MPH,
Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH 

Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH 
Alexander Egeberg, MD, PhD, Lone Skov, MD, PhD, DMSc, Aditya A

Alexander Egeberg, MD, PhD, Lone Skov, MD, PhD, DMSc, Aditya A
Acute transverse myelitis during treatment with etanercept for severe plaque psoriasis  Juan Escalas, PhD, MD, Nicole Knöpfel, MD, Ana Martin-Santiago,

Acute transverse myelitis during treatment with etanercept for severe plaque psoriasis  Juan Escalas, PhD, MD, Nicole Knöpfel, MD, Ana Martin-Santiago,
A girl with a solitary red bulla

A girl with a solitary red bulla
Facial adenocarcinoma treated with intra-arterial chemotherapy

Facial adenocarcinoma treated with intra-arterial chemotherapy
Yul W. Yang, MD, PhD, David J. DiCaudo, MD 

Yul W. Yang, MD, PhD, David J. DiCaudo, MD 
Psoriasis is associated with lipid abnormalities at the onset of skin disease  Lotus Mallbris, MD, PhD, Fredrik Granath, PhD, Anders Hamsten, MD, PhD,

Psoriasis is associated with lipid abnormalities at the onset of skin disease  Lotus Mallbris, MD, PhD, Fredrik Granath, PhD, Anders Hamsten, MD, PhD,
Diffuse hyperpigmented plaques as cutaneous manifestation of multicentric Castleman disease and treatment with thalidomide: Report of three cases  Xiaoqing.

Diffuse hyperpigmented plaques as cutaneous manifestation of multicentric Castleman disease and treatment with thalidomide: Report of three cases  Xiaoqing.
Image registration of sequential transparent photographs to localize and detect new versus recurrent tumors in dermatologic and Mohs micrographic surgery 

Image registration of sequential transparent photographs to localize and detect new versus recurrent tumors in dermatologic and Mohs micrographic surgery 
Baldness reversed by chemotherapy

Baldness reversed by chemotherapy
Megan Wood, MD, Tom Raisanen, MD, Ingrid Polcari, MD 

Megan Wood, MD, Tom Raisanen, MD, Ingrid Polcari, MD 
Efficacy of simvastatin in plaque psoriasis: A pilot study

Efficacy of simvastatin in plaque psoriasis: A pilot study
Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data  Bruce Strober, MD,

Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data  Bruce Strober, MD,
Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 
Vaishali Patel, PharmD, Elizabeth J. Horn, PhD, Steve J

Vaishali Patel, PharmD, Elizabeth J. Horn, PhD, Steve J
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Similar presentations

Ads by Google